Results 131 to 140 of about 214,676 (297)

Toxic epidermal necrolysis and Stevens-Johnson syndrome

open access: yesOrphanet Journal of Rare Diseases, 2010
Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes.
T. Harr, L. French
semanticscholar   +1 more source

Toxic Epidermal Necrolysis and Mortality: A Danish Cohort Study With 30 Years of Follow‐Up

open access: yesThe Journal of Dermatology, Volume 53, Issue 1, Page 35-40, January 2026.
ABSTRACT Toxic epidermal necrolysis (TEN) is a rare, life‐threatening dermatologic condition, typically triggered by medications. While increased short‐term mortality in this group is well documented, few studies have quantified this risk over extended follow‐up.
Ida M. Heerfordt   +5 more
wiley   +1 more source

Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial. [PDF]

open access: yes, 2015
BackgroundToxic epidermal necrolysis (TEN) is a rare systemic allergic drug eruption with high patient mortality. Currently, no established treatments have been shown to be effective for TEN beyond supportive care.
Kim, Kyoungmi   +6 more
core   +4 more sources

Stevens-Johnson syndrome with overlapping features of DRESS syndrome: A report of two cases

open access: yesSAGE Open Medical Case Reports
Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms are severe cutaneous adverse reactions to drugs that are generally considered distinct entities.
Laura D Chin   +3 more
doaj   +2 more sources

Environmental and genetic influences on neurocognitive development: the importance of multiple methodologies and time-dependent intervention [PDF]

open access: yes, 2014
Genetic mutations and environmental factors dynamically influence gene expression and developmental trajectories at the neural, cognitive, and behavioral levels.
Bryson S. E.   +7 more
core   +2 more sources

Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea

open access: yesPLoS ONE, 2016
Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening diseases; however, it is hard to estimate their incidence due to the rarity of these diseases.
Min-Suk Yang   +9 more
semanticscholar   +1 more source

Systemische immunmodulierende Therapien der epidermalen Nekrolyse (Stevens‐Johnson‐Syndrom/toxisch epidermale Nekrolyse): Systematische Übersicht und Metaanalyse

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 1, Page 34-43, January 2026.
Zusammenfassung Hintergrund und Ziele Epidermale Nekrolyse ist eine seltene, aber schwere Hautreaktion mit hoher Letalität. Zur Wirksamkeit systemischer immunmodulatorischer Therapien (SIT) liegt wenig Evidenz vor. Ziel unserer systematischen Übersichtsarbeit war der Vergleich von SIT mit supportiver Therapie oder untereinander.
Ruben Heuer   +3 more
wiley   +1 more source

Tramadol-induced Stevens-Johnson syndrome [PDF]

open access: yes, 2014
Stevens-Johnson syndrome and toxic epidermal necrolysis are acute and severe life-threatening allergic reactions. Their incidences in Thailand may be underestimated due to a lacking of reports.
Limtanyakul, Piyakan   +3 more
core   +1 more source

Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

open access: yesOncologic Critical Care, 2019
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immunologic reactions to several stimuli, mostly medications, which present as a spectrum of primarily widespread mucocutaneous lesions, but also with other organ involvement ...
D. Zimmerman, N. Dang
semanticscholar   +1 more source

Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease–Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis‐Stimulating Agent Dose

open access: yesHemodialysis International, Volume 30, Issue 1, Page 80-100, January 2026.
ABSTRACT Introduction Erythropoiesis‐stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)–related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies ...
Alan Jardine   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy